Aimmune Therapeutics Inc. (AIMT)

29.37
0.03 0.10
NASDAQ : Health Technology
Prev Close 29.40
Open 29.48
Day Low/High 28.92 / 29.63
52 Wk Low/High 16.95 / 29.68
Volume 151.85K
Avg Volume 1.05M
Exchange NASDAQ
Shares Outstanding 63.30M
Market Cap 1.81B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

It Is the 'Flow' of the Action That Matters Most Now

It Is the 'Flow' of the Action That Matters Most Now

What is most notable about this market action is that it never seems to fully discount the optimism about a China trade deal.

The Strong Small-Cap Group Is Keeping Me Optimistic

The Strong Small-Cap Group Is Keeping Me Optimistic

The momentum in the broader market is not that strong and the rotational issue continues.

9 Stocks on My Radar Into Earnings

9 Stocks on My Radar Into Earnings

Don't be too quick to turn negative if there are some pullbacks.

There Are Signs of Improved Technical Action and Stock Picking

There Are Signs of Improved Technical Action and Stock Picking

China trade issue is no longer dominating the action.

My Stock of the Week Is Aimmune Therapeutics

My Stock of the Week Is Aimmune Therapeutics

AIMT has developed a 'desensitivity' treatment for peanut allergies.

Why 3 Biotechs Are Rallying Today

It's a decent start to the trading day as all the major indices are slightly in the green. We are seeing a lot of small biotech stocks I have profiled in these pages rallying on news. Let's start with T2 Biosystems . It is up 25% today as it was awa...

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

AIMT lacks a strong and developed base, so only small long positions should be bought.

Stocks Take Flight on Dovish Fed Comments

Stocks Take Flight on Dovish Fed Comments

Market players are trying to decipher Fed Chair Powell's latest words.

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

There is a bloodbath of selling in medical-related names and severe pressure on cloud-related stocks that have been momentum favorites.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Facebook Is Today's Star as Pockets of Strong Momentum Grow

Facebook Is Today's Star as Pockets of Strong Momentum Grow

It is the action in secondary stocks that is giving the action a much better feel.

There Are a Number of Justifications For Friday's Market Strength

There Are a Number of Justifications For Friday's Market Strength

Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

This Under-the-Radar Biotech Stock Is My Top Pick for 2019

The stock's decline with the sector has occurred despite a steady supply of positive news.

The Market Is Transitioning Back to Stock Picking

The Market Is Transitioning Back to Stock Picking

There are obvious signs that people are trying to put cash to work.

Quiet Trading Allowing Some Biotech Names to Perk Up

Quiet Trading Allowing Some Biotech Names to Perk Up

After two chaotic days, Wall Street is trading relatively calmly, creating opportunities for individual names to show life.

No Market for Old Stock Pickers

No Market for Old Stock Pickers

As long as the indices remain under pressure there is no benefit to picking stocks.

What We Have This Morning Is Some Routine Flipping Into Strength

What We Have This Morning Is Some Routine Flipping Into Strength

My overall market view right now is to maintain a bullish bias but look for some pullbacks to support.

I'm Surprised by How Lifeless the Action Is

I'm Surprised by How Lifeless the Action Is

I find it difficult to believe that there won't be something positive out of the G-20 meeting.

Kohl's Stock Finds Itself Under Heavy Pressure

Kohl's Stock Finds Itself Under Heavy Pressure

The problem KSS faces is that reports from retailers are being automatically sold in this poor market right now.

My Options Strategy for These 2 Biotech Stocks

My Options Strategy for These 2 Biotech Stocks

It's weeks like this that I'm glad I have some 'dry powder' to deploy.

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Let's check out the charts and indicators.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

2 Biotech Stocks to Consider

2 Biotech Stocks to Consider

Many stocks are already at support levels and are offering opportunities to start some positions.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

There Is Still Plenty of Strong, Tradable Action

There Is Still Plenty of Strong, Tradable Action

This market may be extended by just about any measure, but that doesn't mean you should be fighting it.